Genmab A/S at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone, and welcome to the Genmab presentation here at the 2026 JPMorgan Healthcare Conference. My name is Zain Ebrahim. I'm your biotech analyst here at JPMorgan covering Genmab. And from Genmab, it's my great pleasure to welcome the CEO, Jan van de Winkel, who will lead the presentation. And joining him for the Q&A session is Chief Medical Officer, Tahi Ahmadi; and CFO, Anthony Pagano.
Jan, over to you.
/- -
Thank you, Zain for the very nice introduction. It's a pleasure to join you all here once again at the JPMorgan Healthcare Conference as we kick off 2026. Over the past decade, we've taken Genmab from a royalty-based company to a fully integrated innovation-driven biotech with a growing portfolio of proprietary medicines and a powerful late-stage pipeline. Today, I will walk you through how our diversified revenue base and 3 high impact late-stage programs position Genmab
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
